Parallax Volatility Advisers
IMDX

Parallax Volatility Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

Parallax Volatility Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-27
Closed -$3K – 3620
2017
Q4 		$3K Buy
+27
New +$3.04K ﹤0.01% 3852

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallax Volatility Advisers's IMDX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 27 shares — an estimated $3K sold.

Parallax Volatility Advisers first reported a position in IMDX in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 27 Insight Molecular Diagnostics shares in Q1 2018, an estimated $3K.
  • Parallax Volatility Advisers first reported a position in Insight Molecular Diagnostics in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Insight Molecular Diagnostics position peaked at $3K in Q4 2017.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.